Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Azerutamig, an antibody targeting KLRK1 × HER2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bosakitug, an antibody targeting TSLP.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Denrakibart, an antibody targeting CCL17.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pritumumab, an antibody targeting VIM.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Alcestobart, an antibody targeting LAG3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Aletekitug, an antibody targeting IL18.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Urelumab, an antibody targeting 4-1BB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Panobacumab, an antibody targeting Serotype IATS O11.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Otelixizumab, an antibody targeting CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ensituximab, an antibody targeting MUC5AC.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Foralumab, an antibody targeting CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Namilumab, an antibody targeting CSF2.